PF-Atlas › Clinical Trials › NCT07868419

Idiopathic Pulmonary Fibrosis -Related Chronic Cough Reduction With Nalbuphine Extended-Release Tablets

NAL ER · Phase 3

Registry ID
NCT07868419
Phase
Phase 3
Status
Recruiting
Drug / intervention
NAL ER
Sponsor
Trevi Therapeutics
Enrollment
201
Locations
4

About this trial

The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with IPF.

View NCT07868419 on ClinicalTrials.gov →

Explore related

All NAL ER trialsAll IPF trials

Related trials

NAL ER — NCT05964335NAL ER — NCT04030026NAL ER — NCT07671911NAL ER — NCT07036029
Medical disclaimer. This page summarizes public trial data for NCT07868419 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.